Brain 17 Vienna

Brain mets: a particular challenge?

=> Crizotinib: very limited CNS penetrance (< 1%)

Costa et al. J Clin Oncol 2011

• Novel ALK inhibitors: ceritinib and alectinib which are both active against ALK-positive NSCLC • Ceritinib concentration in the CNS may reach approximately 13% of systemic levels in preclinical models

Shaw et al. New Engl J Med 2014 Gadgeel et al. Lancet Oncol 2014 Kim et al. ASCO 2014